ISCO
$0.60
International Stem Cell
$.02
3.45%
ISCO
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Tuesday
Nov 10
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when ISCO reports earnings?
Beat
Meet
Miss

Where is ISCO's stock price going from here?
Up
Flat
Down
Stock chart of ISCO
Analysts
Summary of analysts' recommendations for ISCO
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
International Stem Cell Corporation is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO has developed pluripotent human stem cells from unfertilized human eggs, and techniques to cause those stem cells to be differentiated into the specific cell types required for transplant. It has developed manufacturing protocols to produce the cells minimizing contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesSeattle GeneticsBluebird BioQiagen N.V.RepligenBio-TechneBioCryst Pharmaceuticals